BryanJohnMcColganMD

Endocrinology • Oakland, CA

Lipid Metabolism

Endocrionologist | Clinical Research | Digital Health

Join to view full profile

Dr. McColgan is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. McColgan's full profile

Already have an account?

Office
1270 Excelsior Avenue
Oakland, CA 94610

Education & Training

Stanford Health Care-Sponsored Stanford UniversityFellowship, Endocrinology, Diabetes, and Metabolism, 2014 - 2016
New York Presbyterian Hospital (Columbia Campus)Residency, Internal Medicine, 2011 - 2014
Columbia University Vagelos College of Physicians and SurgeonsClass of 2011

Certifications & Licensure

NY State Medical License 2013 - 2025
CA State Medical License 2014 - 2019
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Endocrinology, Diabetes and Metabolism

Awards, Honors, & Recognition

Member Gold Humanism Honor Society, 2011
Member Alpha Omega Alpha Honor Society, 2011
Inductee Alpha Omega Alpha Honor Medical Society, 2011

Clinical Trials

Safety, Tolerability, and Efficacy of Selonsertib, Firsocostat, and Cilofexor in Adults With Nonalcoholic Steatohepatitis (NASH) Start of enrollment: 2016 Jun 13
Completed
Phase 2
Evaluating the Safety, Tolerability, and Efficacy of GS-9674 in Participants With Nonalcoholic Steatohepatitis (NASH) Start of enrollment: 2016 Oct 26
Completed
Phase 2
Study to Evaluate Safety, Tolerability, and Efficacy of GS-0976 in Adults With Nonalcoholic Steatohepatitis Start of enrollment: 2016 Aug 08
Completed
Phase 2
Study to Evaluate the Pharmacokinetics of Firsocostat or Fenofibrate in Adults With Normal and Impaired Hepatic Function Start of enrollment: 2016 Sep 23
Completed
Phase 1
Study to Evaluate the Safety and Efficacy of Selonsertib, Firsocostat, Cilofexor, and Combinations in Participants With Bridging Fibrosis or Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis (NASH) Start of enrollment: 2018 Mar 21
Completed
Phase 2
Join now to see all

Publications & Presentations

PubMed

146 citations
Acetyl-CoA Carboxylase Inhibitor GS-0976 for 12 Weeks Reduces Hepatic De Novo Lipogenesis and Steatosis in Patients With Nonalcoholic Steatohepatitis.
Eric Lawitz, Angie Coste, Fred Poordad, Naim Alkhouri, Nicole Loo
Clinical Gastroenterology and Hepatology. 2018-12-01
234 citations
Simtuzumab Is Ineffective for Patients With Bridging Fibrosis or Compensated Cirrhosis Caused by Nonalcoholic Steatohepatitis
Stephen A. Harrison, Manal F. Abdelmalek, Stephen H. Caldwell, Mitchell L. Shiffman, Anna Mae Diehl
Gastroenterology. 2018-10-01
116 citations
Simtuzumab for Primary Sclerosing Cholangitis: Phase 2 Study Results With Insights on the Natural History of the Disease
Andrew J. Muir, Cynthia Levy, Harry L.A. Janssen, Aldo J. Montano-Loza, Mitchell L. Shiffman
Hepatology. 2019-02-01

Professional Memberships

Alpha Omega Alpha Honor Medical Society - AOA
Fellow

External Links

Online Portfoliohttp://www.bryanmccolgan.com